Form 4: Vaxcyte CEO Grant Pickering Sells Shares Under 10b5-1 Trading Plan

Vaxcyte CEO Grant Pickering sold shares of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Grant Pickering, CEO of Vaxcyte, Inc., reported the sale of common stock on April 1, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• A total of 2,616 shares were sold at weighted average prices ranging from $66.02 to $68.10.
• Following the transactions, Pickering directly owns 477,847 shares.
• Additionally, 147,362 to 147,780 shares are held indirectly through children's trusts.
• The sales were conducted at various prices, with the reporting person committed to providing full details upon request to the SEC, the issuer, or a security holder.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales by an executive. The sales were conducted under a pre-arranged trading plan, suggesting no immediate negative implications for the company's prospects.

Industry Context

Sales by company executives are a normal part of corporate governance. It is important to note that the sales were executed under a pre-arranged 10b5-1 trading plan, which is a common practice to avoid accusations of insider trading.

Key Dates